中生利润同比增长140%;辉瑞镰状细胞病新药III期未达主要终点

氨基观察
Yesterday

多家药企发布半年报。8月18日,中国生物制药发布2025年半年报。报告期内,公司营业收入175.7亿元,同比增长10.7%;净利润33.9亿元,同比增长140%。同一日,科伦博泰生物发布2025年半年报。报告期内,公司营业收入9.5亿元,同比下降31.3%;亏损额1.45亿元。对于它们的业绩,你怎么看?辉瑞再遇挫折。8月15日,辉瑞宣布inclacumab(PF-07940370)治疗镰状细胞病(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10